• Title/Summary/Keyword: 저류암

Search Result 43, Processing Time 0.021 seconds

Inorganic and Organic Geochemical Characteristics of Devonian Bitumen Carbonate in Alberta, Canada (캐나다 데본기 비투멘 탄산염암의 무기 및 유기 지화학적 특성 연구)

  • Choi, Ji-young;Kim, Ji-Hoon;Kil, Yong-Woo;Lee, Sung-Dong;Park, Myong-Ho
    • Economic and Environmental Geology
    • /
    • v.44 no.1
    • /
    • pp.21-35
    • /
    • 2011
  • Inorganic and organic geochemical characteristics of Devonian bitumen carbonates in Alberta were studied using two drilling cores, Saleski 03-34-88-20w4 and Saleski 08-01-88-20w4, taken from the Core Research Center of Canada. The results of elements analyses showed high Total Inorganic Carbon, low Total Nitrogen and Total Sulfur, and Rock-Eval pyrolysis showed double $CO_2$ peaks in the oxidation part. These mean that the Devonian bitumen carbonates are mainly composed of dolomite formed by diagenesis, and its crystal texture is dominantly subhedral to anhedral but often euhedral. Bitumen contents were 3.6~19.0% in Saleski 3-34-88-20w4 and 5.0~16.4% in Saleski 08-01-88-20w4, respectively. As samples color become dark, bitumen and Total Organic Carbon contents are generally increasing in two cores. The results of biomarker analyses showed that the contents of resins and asphaltenes were 5~28% higher than those of saturated hydrocarbon, interring that the bitumen has been heavily biodegradated. According to the results of carbon isotope analyses in each component of bitumen, asphaltenes had highest values and the others had constant values. However, their values were varied in the range of normal crude oil (-18~-30‰).

Talc Pleurodesis via Video-Assisted Thoracoscopic Surgery(VATS) in Malignant Pleural Effusions (악성 흉막삼출 환자에서 비디오 흉강경을 이용한 Talc 흉막유착술)

  • Park, Sang-Joon;Ahn, Seok-Jin;Kang, Kyeong-Woo;Koh, Young-Min;Suh, Gee-Young;Chung, Man-Pyo;Kim, Ho-Joong;Kwon, O-Jung;Kim, Kwhan-Mien;Kim, Jhin-Gook;Shim, Young-Mog;Rhee, Chong-H
    • Tuberculosis and Respiratory Diseases
    • /
    • v.45 no.4
    • /
    • pp.785-794
    • /
    • 1998
  • Background: Chemical pleurodesis is a widely used method for the control of symptomatic and recurrent malignant pleural effusions. Talc has been accepted to be the most effective sclerosing agent for chemical pleurodesis. This study was undertaken to evaluate the usefulness of talc pleurodesis via video-assisted thoracoscopic surgery (VATS) in treatment of malignant pleural effusions. Methods : A retrospective analysis of the medical records and radiographic findings was performed. The success of the procedure was defined as daily pleural fluid drainage below 100ml within 1 week after pleurodesis and complete expansion of the lung on simple chest radiograph. Recurrence was defined as reaccumulation of pleural fluid on follow-up chest radiographs, and complete response as no fluid accumulation on follow-up chest radiographs. Results: Between October 1994 and August 1996, talc pleurodesis via VATS was performed in 35 patients. Duration of follow-up ranged from 5 days to 828 days(median 79days). The initial success rate of procedure was 88.6%(31 of 35 cases). Complete responses were observed in 92.8% at 30 days, 75.7% at 90 days and 64.9% at 180 days. Postoperative complications were fever (54.3%), subcutaneous emphysema(11.4%), reexpansion pulmonary edema(2.9%) and respiratory failure(5.7%). But procedure related mortality or respiratory failure was not found. Conclusion: Talc pleurodesis via VATS is a safe and effective method for the control of symptomatic malignant pleural effusions.

  • PDF

Analysis of Prognostic Factors Related to Survival Time for Patients with Small Cell Lung Cancer (소세포폐암 환자의 생존기간에 관련된 인자 분석)

  • Kim, Hee-Kyoo;Yook, Dong-Seung;Shin, Ho-Sik;Kim, Eun-Seok;Lim, Hyun-Jeung;Lim, Tae-Kwan;Ok, Chul-Ho;Cho, Hyun-Myung;Jung, Maan-Hong;Jang, Tae-Won
    • Tuberculosis and Respiratory Diseases
    • /
    • v.54 no.1
    • /
    • pp.57-70
    • /
    • 2003
  • Background : Small cell lung cancer represents approximately 20% of all carcinomas of the lung, and is recognized as having a poor long term outcome compared to non-small cell lung cancer. Therefore, this study investigated the prognostic factors in small cell lung cancer patients in order to improved the survival rate by using the proper therapeutic methods. Material and method : The clinical data from 394 patients who diagnosed with small cell lung cancer and treated from 1993 to 2001 at the Kosin University Gospel Hospital, were analyzed. Result : There were 314 male patients (79.7%), and 80 female patients (20.3%). The number of those with limited disease was 177 (44.9%), and the number of those with extensive disease was 217 (55.1%). Overall, 366 out of 394 enrolled patients had died. The median survival time was 215 days (95% CI : 192-237days). The disease stage, Karnofsky performance state, 5% body weight loss for the recent 3 months, chemotherapy regimens, and the additive chest radiotherapy were identified as being statistically significant factors for the survival time. The median survival times of the supportive care group, one anticancer therapy, and two or more treatment groups were 17 days, 211 days, and 419 day, respectively (p<0.001). These data emphasize the importance of anticancer treatment to improve survival time for patients. The group of concurrent chemoradiotherapy (30 patients) showed significantly longer survival time than the group given sequential chemoradiotherapy (55 patients) (528 days versus 373 days, p=0.0237). The favorable prognostic factors of laboratory study were groups of leukocyte =8,000/mm3, ALP=200 U/L, LDH=450 IU/L, NSE=15 ng/mL, s-GOT=40 IU/L. In extensive disease, there was no difference according to the number of metastatic site. However, the median survival time of patients with ipsilateral pleural effusion had longer than patients having other metastatic sites. According to the survey periods, three groups were divided into 1993-1995, 1996-1998, and 1999-2001. The median survival time was significantly prolonged after 1999 in comparison to previous groups (177 days, 194 days, 289 days, p=0.001, 0.002, respectively). Conclusion: Disease stage and 5% body weight loss for recent 3 months at diagnostic state were significant prognostic factors. In addition, the performance status, serum ALP, LDH, NSE, CEA levels also appear to be prognostic factors. The survival time of those patients with small cell lung cancer has been prologned in recent years. It was suggested that the used of the EP (etoposied and cisplatin) chemotherapy method and concurrent chemoradiotherapy for patients with a limited stage contributed to the improved survival time.